Addex regains global rights to GABAB PAM assets from Indivior
Bitget2026/09/25 05:00- Addex Therapeutics regained full global rights to its GABAB positive allosteric modulator portfolio from Indivior on Sept. 25, 2026.
- Transaction returns a development candidate Indivior had selected, giving Addex full ownership and control of future development.
- Rights reversion followed Indivior’s R&D rationalization tied to the planned merger of its parent with Supernus Pharmaceuticals.
- Addex plans to weigh options, including new partnering discussions or further internal development of the substance use disorder candidate.
- Returned asset expands Addex’s GABAB PAM pipeline alongside its wholly owned chronic cough program.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
WikiLeaks Founder Julian Assange Welcomes Daughter With Terminator Quote
Crypto prices
More
